

Gemina Labs Announces Addition to Its IP Portfolio

VANCOUVER, BC / April 9, 2024 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the "Company" or "Gemina") today announces that it has licensed a novel biosensing architecture from the University of British Columbia.

This licence is the culmination of a programme of research commenced between Gemina and the University of British Columbia in 2021. It lays the foundation for expanding Gemina's technology portfolio to include point-of-care biosensors chips to enable low-cost, high-sensitivity detection of molecular amplification products, small molecules, and proteins. This opens the door to affordable single-use molecular assays for high-sensitivity diagnosis of infections like Mycobacterium tuberculosis with a novel test kit designed to meet the WHO high-priority target product profiles for new tuberculosis diagnostics. This is another step forward for Gemina to help meet the global health challenge to #EndTB2030. The licensed technology is the subject of a new patent application.

It's a programme of work that's highly consistent with Gemina's strategy of demonstrating that its core technology platform is widely applicable across point-of-care diagnostics, over and above the Company's first focus on improving the performance of lateral flow assays.

Commenting today, Robert Greene, Gemina's CTO, said "One of the great privileges of my role is to be able to partner with exciting researchers at the forefront of their field. Our UBC partnership with Dr. Clifford is an outstanding example of industrial-academic collaboration and we're delighted with the research results that we've been able to achieve, which now form an important addition to Gemina's growing IP-engine".

On Behalf of the Board of Directors

Brian Firth
CEO
Gemina Laboratories Ltd.

About Gemina Laboratories Ltd.

Gemina Labs is a point-of-care diagnostics technology company with a family of transformative, patented, proprietary technologies that power next-generation testing platforms for a wide range of diagnostic targets that affect human health and wellness. Our technology drives testing platforms that are portable, affordable, accurate, and simple to use. Our development pipeline includes proprietary designs for multiple point-of-care diagnostic form factors, including lateral flow assays, biosensors, and molecular assays. Additional information on the Company can be found at www.geminalabs.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this Release.

Forward-Looking Statements

This news release includes forward-looking information and statements, which may include, but are not limited to, information and statements regarding or inferring the future business, operations, financial performance, prospects, and other plans, intentions, expectations, estimates, and beliefs of the Company. Such statements include statements regarding the anticipated terms of any proposed transaction or engagement. Information and statements which are not purely historical fact are forward-looking statements. Forward-looking information and statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking information and statements herein. Although the Company believes that any forward-looking information and statements herein are reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such information and statements, there can be no assurance that any such forward-looking information and statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance upon such forward-looking information and statements. Furthermore, the Company is presently unable to fully quantify the impact that the Covid-19 pandemic will have on its operations and recognizes that certain eventualities may affect planned or assumed performance moving forward. As such, any forward-looking information and statements herein are made as of the date hereof, and except as required by applicable laws, the Company assumes no obligation and disclaims any intention to update or revise any forward-looking information and statements herein or to update the reasons that actual events or results could or do differ from those projected in any forward looking information and statements herein, whether as a result of new information, future events or results, or otherwise, except as required by applicable laws.

For more information regarding the Company, please contact:

Gemina Laboratories Ltd

Brian Firth, Chief Executive Officer

Email: investor@geminalabs.com